CDC37 as a novel target for the treatment of NPM1-ALK expressing anaplastic large cell lymphomas

[1]  Jin-jian Lu,et al.  Targeting the Hsp90-Cdc37-client protein interaction to disrupt Hsp90 chaperone machinery , 2018, Journal of Hematology & Oncology.

[2]  R. Jensen,et al.  When the good go bad: Mutant NPM1 in acute myeloid leukemia. , 2017, Blood reviews.

[3]  M. Wasik,et al.  Nucleophosmin-anaplastic lymphoma kinase: the ultimate oncogene and therapeutic target. , 2017, Blood.

[4]  A. Shaw,et al.  Targeting ALK: Precision Medicine Takes on Drug Resistance. , 2017, Cancer discovery.

[5]  M. Sattler,et al.  Hsp90·Cdc37 Complexes with Protein Kinases Form Cooperatively with Multiple Distinct Interaction Sites* , 2015, The Journal of Biological Chemistry.

[6]  K. Dzwonek,et al.  Activating mutations in ALK kinase domain confer resistance to structurally unrelated ALK inhibitors in NPM-ALK-positive anaplastic large-cell lymphoma , 2014, Journal of Cancer Research and Clinical Oncology.

[7]  Hongwei Ma,et al.  Targeting levels or oligomerization of nucleophosmin 1 induces differentiation and loss of survival of human AML cells with mutant NPM1. , 2011, Blood.

[8]  Lin Qiu,et al.  Celastrol, a novel HSP90 inhibitor, depletes Bcr-Abl and induces apoptosis in imatinib-resistant chronic myelogenous leukemia cells harboring T315I mutation. , 2010, Cancer letters.

[9]  J. Buchner,et al.  The Hsp90 Chaperone Machinery* , 2008, Journal of Biological Chemistry.

[10]  Nadinath B. Nillegoda,et al.  Cdc37 has distinct roles in protein kinase quality control that protect nascent chains from degradation and promote posttranslational maturation , 2007, The Journal of cell biology.

[11]  Peter G. Schultz,et al.  Identification of NVP-TAE684, a potent, selective, and efficacious inhibitor of NPM-ALK , 2007, Proceedings of the National Academy of Sciences.

[12]  T. Hunter,et al.  The Protein Kinase Complement of the Human Genome , 2002, Science.

[13]  B. Falini,et al.  Nucleophosmin-anaplastic lymphoma kinase (NPM-ALK), a novel Hsp90-client tyrosine kinase: down-regulation of NPM-ALK expression and tyrosine phosphorylation in ALK(+) CD30(+) lymphoma cells by the Hsp90 antagonist 17-allylamino,17-demethoxygeldanamycin. , 2002, Cancer research.

[14]  S. Korsmeyer,et al.  BCL-2 family members and the mitochondria in apoptosis. , 1999, Genes & development.

[15]  S. Lee,et al.  CD30/TNF receptor-associated factor interaction: NF-kappa B activation and binding specificity. , 1996, Proceedings of the National Academy of Sciences of the United States of America.